Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2017 vs Humira in Rheumatoid Arthritis
NCT02744755Phase 3Completed
- Sponsor
- Sandoz
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Sandoz. Primary endpoint: Change in DAS28-CRP Score From Baseline at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02744755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744755.